|Breast cancer classification and prognosis based on gene expression profiles from a population-based study|
C Sotiriou, SY Neo, LM McShane, EL Korn, PM Long, A Jazaeri, P Martiat, ...
Proceedings of the National Academy of Sciences 100 (18), 10393-10398, 2003
|Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis|
C Sotiriou, P Wirapati, S Loi, A Harris, S Fox, J Smeds, H Nordgren, ...
Journal of the National Cancer Institute 98 (4), 262-272, 2006
|International network of cancer genome projects|
International Cancer Genome Consortium
Nature 464 (7291), 993, 2010
|Gene-expression signatures in breast cancer|
C Sotiriou, L Pusztai
New England Journal of Medicine 360 (8), 790-800, 2009
|The landscape of cancer genes and mutational processes in breast cancer|
PJ Stephens, PS Tarpey, H Davies, P Van Loo, C Greenman, DC Wedge, ...
Nature 486 (7403), 400-404, 2012
|Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group|
M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ...
Journal of the National cancer Institute 103 (22), 1656-1664, 2011
|Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer|
M Buyse, S Loi, L Van't Veer, G Viale, M Delorenzi, AM Glas, ...
Journal of the National Cancer Institute 98 (17), 1183-1192, 2006
|The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014|
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2015
|Landscape of somatic mutations in 560 breast cancer whole-genome sequences|
S Nik-Zainal, H Davies, J Staaf, M Ramakrishna, D Glodzik, X Zou, ...
Nature 534 (7605), 47-54, 2016
|Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition …|
S Loi, N Sirtaine, F Piette, R Salgado, G Viale, F Van Eenoo, G Rouas, ...
J Clin Oncol 31 (7), 860-867, 2013
|70-gene signature as an aid to treatment decisions in early-stage breast cancer|
F Cardoso, LJ van’t Veer, J Bogaerts, L Slaets, G Viale, S Delaloge, ...
New England Journal of Medicine 375 (8), 717-729, 2016
|Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series|
C Desmedt, F Piette, S Loi, Y Wang, F Lallemand, B Haibe-Kains, G Viale, ...
Clinical cancer research 13 (11), 3207-3214, 2007
|Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients|
E De Azambuja, F Cardoso, G de Castro, M Colozza, MS Mano, ...
British journal of cancer 96 (10), 1504-1513, 2007
|Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures|
P Wirapati, C Sotiriou, S Kunkel, P Farmer, S Pradervand, B Haibe-Kains, ...
Breast Cancer Research 10 (4), R65, 2008
|Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial|
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ...
Annals of oncology 25 (8), 1544-1550, 2014
|Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade|
S Loi, B Haibe-Kains, C Desmedt, F Lallemand, AM Tutt, C Gillet, P Ellis, ...
Journal of clinical oncology 25 (10), 1239, 2007
|Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes|
C Desmedt, B Haibe-Kains, P Wirapati, M Buyse, D Larsimont, ...
Clinical cancer research 14 (16), 5158-5165, 2008
|The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models|
Nature biotechnology 28 (8), 827, 2010
|Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative …|
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
J Clin oncol 33 (9), 983-991, 2015
|hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer|
C Camps, FM Buffa, S Colella, J Moore, C Sotiriou, H Sheldon, AL Harris, ...
Clinical cancer research 14 (5), 1340-1348, 2008